Emcure Pharma share price jumps nearly 6% on robust Q2 FY25 results; check details

In early trade, the stock jumped as much as 5.9% to ₹1,525 per share on the NSE. However, at 10 am, the scrip pared gains and was trading at ₹1,447 per share, up 0.5%.

Emcure Pharmaceuticals Q2 results

The company's consolidated net profit increased 38.2% to ₹201.5 crore in the second quarter of FY25. In the year-ago period, the post-tax profit stood at ₹145.8 crore.

Revenue from operations rose 20.3% to ₹2,001.9 crore in the July-September quarter of the current fiscal, compared to ₹1,663 crore in Q2 FY24.

In an exchange filing, the company said that the September quarter witnessed strong growth in international businesses, growing 25% year-on-year (YoY) and 18% quarter-on-quarter (QoQ). The Canadian business performed well, attaining a 51% YoY growth. The rest of the world business also rose 29% YoY.

Emcure said that it is seeing strong traction in its key focus markets. The company’s domestic business grew over 15% to ₹933 crore.

Regarding financial performance, Satish Mehta, CEO and Managing Director of the company, said, “Emcure witnessed a strong performance in Q2. We have made significant investments in both our International and Domestic businesses over the past 2 years and the benefits of these efforts are starting to particularly reflect in the growth of our International business."

"Our recent inorganic additions – Sanofi partnership in India and Mantra acquisition in Canada – are now fully integrated and our focus is now on deriving both revenue and operational synergies. Moving forward, we aim to enhance the margins by leveraging operating efficiencies while continuing to drive strong growth in both Indian and International markets through new product launches and market share gains," he added.